You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
仙樂健康(300791.SZ):2019年淨利降29.87%至1.43億元 擬10轉5派3元
格隆匯 04-24 09:04

格隆匯4月24日丨仙樂健康(300791.SZ)披露2019年年度報告,報告期內,公司實現營業收入15.80億元,同比下降0.99%;歸屬於上市公司股東的淨利潤1.43億元,同比下降29.87%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.30億元,同比下降31.51%;經營活動現金淨流入2.32億元,同比增長26.25%;基本每股收益2.19元,年報推10轉5派3元(含税)。

2019年,公司研發投入6578.50萬元,同比增長6.00%,主要覆蓋技術平台建設、技術拓展與創新項目、配方研究和開發等。公司在內部開展14項技術創新項目,提交發明專利申請10項,完成多個新產品研究開發和上市,包括多款益生菌類新品和複雜配方口感豐富固體飲料新品。

由於馬鞍山軟糖項目投產及訂單轉移期間試生產費用、固定攤銷費用、管理費用較大,同時新的生產設備所具有的更強生產功能也使得公司加大了生產工藝開發方面的投入,報告期內軟糖總體毛利率下降22.81個百分點至15.38%。

但隨着營養軟糖產能向馬鞍山轉移工作的結束和產能釋放,公司營養軟糖產品的毛利率逐步提升,軟糖產能瓶頸和客户訂單增長的需求也得以解決。完成軟糖生產轉移後,公司着手將汕頭生產基地原有軟糖車間改造為益生菌軟糖專用車間,現已完成並投產。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account